Crossmark

Management of Embolic Stroke of Undetermined Source (ESUS)

Crossref DOI link: https://doi.org/10.1007/s40265-018-0912-8

Published Online: 2018-05-08

Published Print: 2018-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Geisler, Tobias

Mengel, Annerose

Ziemann, Ulf

Poli, Sven
License Information

Text and Data Mining valid from 2018-05-08
More Information

Article History

First Online: 8 May 2018

Compliance with Ethical Standards

:

: No external funding was used in the preparation of this manuscript.

: Tobias Geisler reports personal fees from AstraZeneca, Boehringer Ingelheim, Pfizer, and MSD; grants and personal fees from Bayer Healthcare, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, and The Medicines Company; and grants from Siemens Healthcare and Spartan Bioscience, outside the submitted work. Annerose Mengel has no conflicts of interest relevant to the presented work. Ulf Ziemann has received speaker honoraria and/or travel compensation from Bayer Vital GmbH, Biogen Idec GmbH, Bristol Myers Squibb GmbH, Medtronic GmbH, and Pfizer GmbH; and grants from Biogen Idec GmbH, Servier, and Janssen Pharmaceuticals NV. He serves on the advisory board of CorTec GmbH. None of the above are related to the submitted work. Sven Poli has received speaker’s honoraria and consulting honoraria from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, Daiichi Sankyo and Werfen; reimbursement for congress traveling and accommodation from Bayer and Boehringer Ingelheim; and research support from Bristol-Myers Squibb/Pfizer, Boehringer-Ingelheim, Daiichi Sankyo and Helena Laboratories. None of the above are related to the submitted work.